文献速递头颈与中枢神经肿瘤支持与姑息治疗

质子泵抑制剂使用与复发性胶质母细胞瘤患者结局的关联

Association of proton pump inhibitor use with outcome of patients with recurrent glioblastoma.
PubMed 文献 · Eur J Cancer · 2026-01-09

该研究 pooled 分析了四项复发性胶质母细胞瘤临床试验,评估具有强乙醛脱氢酶1A1激活特性的质子泵抑制剂(PA-PPI)使用与结局的关联。单变量分析中PA-PPI使用与基线及第8、16周的总生存期较差相关,但多变量分析控制主要预后因素后不再显著,且类固醇使用使PA-PPI使用变得不显著。在复发性胶质母细胞瘤中无证据表明PA-PPI使用会影响结局。

要点

  • 复发性胶质母细胞瘤中PA-PPI使用与总生存期较差相关仅见于单变量分析。
  • 多变量分析控制预后因素后PA-PPI使用不再显著,类固醇使用是混杂因素。
  • 复发性胶质母细胞瘤中无证据表明PA-PPI使用损害结局。

核心结论

  • 在复发性胶质母细胞瘤患者中,未发现PA-PPI使用影响结局的证据。

研究设计与样本

  • 对四项复发性胶质母细胞瘤临床试验(DIRECTOR、EORTC 1410、EORTC 1608 C臂、EORTC 26034)进行汇总分析。
  • 在基线和第8周、第16周两个界标点评估PA-PPI使用,采用Cox模型分析结局关联。

主要发现

  • 单变量分析中,PA-PPI使用在基线和两个界标点均与总生存期较差相关,但与无进展生存期无关。
  • 多变量分析控制主要预后因素后,PA-PPI使用不再具有预后意义。
  • 从多变量Cox模型剔除不同预后因素发现,类固醇使用使PA-PPI使用变得不显著,且PA-PPI使用与类固醇使用相关。

临床怎么用

  • 鉴于存在替代药物,胶质母细胞瘤患者中PA-PPI处方的适应症可能需要收窄。

局限性

  • 复发性胶质母细胞瘤中一线治疗明确的结局关联与MGMT启动子甲基化无关,而复发设置中无关联,可能与处方模式变化有关,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of proton pump inhibitors with strong aldehyde dehydrogenase 1A1-activating properties (PA-PPI) has recently been associated with inferior outcomes in patients with newly diagnosed glioblastoma. While the mechanisms mediating such outcome associations remain incompletely understood, no such data have been generated for patients with recurrent glioblastoma. MATERIALS AND METHODS: We conducted a pooled analysis of four clinical trials in the setting of first recurrence of glioblastoma: DIRECTOR (NCT00941460), EORTC 1410 (NCT02343406), EORTC 1608 (arm C) (NCT03224104), and EORTC 26034 (NCT00086879). We assessed PA-PPI use at baseline and at two defined landmarks, week 8 and week 16. Cox models were used to identify associations of PA-PPI use with outcome. RESULTS: On univariate analysis, PA-PPI use was associated with inferior overall survival, but not progression-free survival, at baseline and at both landmarks. However, PA-PPI use was no longer prognostic in multivariable analyses controlling for major prognostic factors. Omission of distinct prognostic factors from the multivariate Cox models revealed that steroid use made PA-PPI use insignificant. Indeed, PA-PPI use was associated with steroid use. DISCUSSION: The present analysis of prognostic outcome associations of PA-PPI use in patients with recurrent glioblastoma provides no evidence that PA-PPI use may compromise outcome in this setting. The disconnect between clear outcome associations in the first-line setting, without a link to MGMT promoter methylation, versus no associations in the recurrent setting may be linked to changing prescriptions patterns, but requires further studies. Since alternative medications are available, the indications for PA-PPI prescription should probably be narrowed in patients with glioblastoma.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Le Rhun E, Sain D, van den Bent M, et al. Association of proton pump inhibitor use with outcome of patients with recurrent glioblastoma. Eur J Cancer. 2026. PMID: 41548362. doi:10.1016/j.ejca.2026.116225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。